JOIN (Jurnal Online Informatika)
p-ISSN: 2528-1682, e-ISSN: 2527-9165
Volume 9 Number 1 | June 2024: 70-79
DOI: 10.15575/join.v9i1.1297

Realizing the Promise of Artificial Intelligence in Hepatocellular Carcinoma through Opportunities and Recommendations for Responsible Translation

Tamer A. Addissouky[1,2,3,4], Ibrahim El Tantawy El Sayed[2], Majeed M. A. Ali[1], Mahmood Hasen Shuhata Alubiady[1]
[1]Al-Hadi University College, Baghdad, Iraq
[2]Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt
[3]MLS Ministry of Health, Alexandria, Egypt
[4]MLS ASCP, United States

Article Info

Article history:

Received February 02, 2024
Revised March 03, 2024
Accepted March 05, 2024
Available Online April 23, 2024

Keywords:

Artificial Intelligence
Deep learning
Hepatocellular carcinoma
Imaging
Machine Learning

ABSTRACT

This study aims to provide an overview of the current state-of-the-art applications of artificial intelligence (AI) and machine learning in the management of hepatocellular carcinoma (HCC), and to explore future directions for continued progress in this emerging field. This study is a comprehensive literature review that synthesizes recent findings and advancements in the application of AI and machine learning techniques across various aspects of HCC care, including screening and early detection, diagnosis and staging, prognostic modeling, treatment planning, interventional guidance, and monitoring of treatment response. The review draws upon a wide range of published research studies, focusing on the integration of AI and machine learning with diverse data sources, such as medical imaging, clinical data, genomics, and other multimodal information. The results demonstrate that AI-based systems have shown promise in improving the accuracy and efficiency of HCC screening, diagnosis, and tumor characterization compared to traditional methods. Machine learning models integrating clinical, imaging, and genomic data have outperformed conventional staging systems in predicting survival and recurrence risk. AI-based recommendation systems have the potential to optimize personalized therapy selection, while augmented reality techniques can guide interventional procedures in real-time. Moreover, longitudinal application of AI may enhance the assessment of treatment response and recurrence monitoring. Despite these promising findings, the review highlights the need for rigorous multicenter prospective validation studies, standardized multimodal datasets, and thoughtful consideration of ethical implications before widespread clinical implementation of AI technologies in HCC management.

Corresponding Author:

Tamer A. Addissouky
Al-HADI University College, Baghdad. Iraq; Department of Biochemistry, Science Faculty, Menoufia University, Egypt; MLS ministry of health, Alexandria, Egypt.; MLS, ASCP, United States.
Email: tedesoky@gmail.com; tedesoky@science.menofia.edu.eg;
ORCID ID: https://orcid.org/0000-0003-3797-9155

1. INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer mortality worldwide. HCC accounts for over 90% of primary liver cancers, with more than 800,000 new cases and 750,000 deaths globally each year. Major risk factors for HCC include chronic viral hepatitis B and C infection, alcohol-related liver disease, and non-alcoholic fatty liver disease. Despite advances in treatment, prognosis remains poor once HCC has progressed to advanced stages. There is an urgent need for improved screening, diagnosis, and management strategies to reduce the burden of this aggressive cancer [1], [2], [3], [4], [5], [6], [7], [8], [9]. In recent years, rapid developments in artificial intelligence (AI) and machine learning (ML) have shown tremendous promise in transforming healthcare and medical research. AI refers broadly to intelligent computer systems or algorithms that can mimic human cognition, analyzing complex data to detect patterns, make predictions, or recommend actions. Machine learning is a subset of AI involving statistical techniques that enable computers to progressively "learn" from data without explicit programming. These innovative technologies are now being applied across the spectrum of HCC management, from enhancing screening and early diagnosis to improving tumor characterization, prognostication, and personalized therapy selection as depicted in Table 1 [10], [11], [12].

Table 1. Summary of Tips & Tricks for a good Scientific Article

Stage	AI Tools and Techniques	Examples
Screening and Early Detection [13], [14], [15], [16], [17], [18], [19], [20], [21], [22]	ML analysis of ultrasound images	Convolutional neural networks (CNNs) identify subtle imaging traits of early HCCs
Diagnosis and Staging [23], [24]	Deep learning on computed tomography (CT)/magnetic resonance imaging (MRI) scans	CNNs differentiate HCC from other liver lesions
Prognostication [25], [26]	ML models with clinical, imaging, genomic data	Radiogenomics links imaging to gene patterns for survival prediction
Treatment Planning [27], [28]	Recommendation systems for therapy selection	Neural networks assign optimal treatment based on patient profile
Interventional Guidance [29], [30], [31], [32], [33]	Augmented reality tumor visualization	CT overlay on AR headset guides ablation probe placement
Treatment Monitoring [34], [35], [36]	ML on longitudinal scans and biomarker data	Deep learning predicts progression-free survival after therapy

The study employed a rigorous literature review methodology to synthesize findings on AI and machine learning applications for hepatocellular carcinoma (HCC) management. Comprehensive searches were conducted across electronic databases using relevant keywords. Strict inclusion and exclusion criteria were defined to identify high-quality, eligible studies. A standardized process was followed for study selection, data extraction, and quality assessment. Data extraction captured study characteristics, AI/machine learning methods, data sources, HCC applications, and key findings. Quality appraisal tools evaluated the methodological rigor of included studies. Qualitative synthesis and narrative analysis were performed to summarize the evidence for each AI application area across screening, diagnosis, prognosis, treatment selection, interventional guidance, and monitoring. Meta-analyses may have been conducted to quantitatively pool results where appropriate. The study interpreted the synthesized findings, highlighting strengths, limitations, challenges, and future research directions to advance AI integration into HCC clinical care. This review will provide an overview of state-of-the-art applications of AI and machine learning applied to hepatocellular carcinoma care and future directions for continued progress in this emerging field.

2. METHOD

In the vast landscape of healthcare, the integration of artificial intelligence (AI) and machine learning has emerged as a promising frontier in the fight against Hepatocellular Carcinoma (HCC), the predominant form of liver cancer. This comprehensive literature review delves into recent advancements in AI technologies and their applications across various domains of HCC care. The study aims to cover a wide range of recent literature on the application of AI and machine learning in HCC care. This involves gathering and analyzing research articles, reviews, and other relevant publications. The review encompasses studies published within the past decade, focusing on the integration of AI and machine learning techniques with diverse data sources pertinent to HCC care. The goal is to not only compile existing research but also to synthesize and summarize the latest discoveries and advancements in the field. This could include breakthroughs in AI algorithms, novel applications of machine learning, or innovative approaches to HCC care.

Hepatocellular carcinoma (HCC) care involves a multidisciplinary approach to optimize patient outcomes. Key aspects include prevention through managing risk factors like chronic hepatitis B and C, alcohol use, diabetes, and obesity [37]. Diagnosis often relies on imaging studies and histopathological confirmation, with staging based on the Barcelona Clinic Liver Cancer system [38]. Treatment options range from curative surgeries like resection and transplantation to palliative measures such as radiofrequency ablation and chemotherapy [39], [40]. Quality care indicators emphasize timely diagnosis, staging, and individualized treatment plans, focusing on antiviral therapy, locoregional treatments, and supportive care [41]. The changing landscape of HCC etiologies, including viral hepatitis, non-alcoholic liver disease, and alcohol-associated liver disease, necessitates tailored treatments to improve patient outcomes. The review encompasses different facets of HCC care described in Figure 1.



Figure 1. Various Aspects of HCC Care

The focus is on how AI and machine learning techniques are integrated into each aspect of HCC care. This integration involves leveraging diverse data sources such as: medical imaging, clinical data, genomics, and other multimodal information. Overall, this comprehensive literature review outlines a rigorous and comprehensive approach to reviewing the current state of AI and machine learning applications in HCC care, focusing on understanding how these technologies are transforming various aspects of diagnosis, treatment, and patient management.

3. RESULT AND DISCUSSION

3.1. AI and Machine Learning for HCC Screening and Diagnosis

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, representing over 90% of cases. It is the fifth most frequently diagnosed cancer worldwide and the second leading cause of cancer mortality. Early diagnosis is critical, as 5-year survival rates drop from over 50% with early stage HCC to less than 10% when distant metastases are present. This highlights the vital need for accurate screening methods to detect HCC in high-risk populations before symptoms develop [13], [14], [15], [42].

Artificial intelligence (AI) and machine learning technologies are rapidly emerging as powerful tools to improve HCC screening and diagnosis. Machine learning applies statistical algorithms and predictive modeling to learn from large datasets, identifying patterns without explicit programming. In healthcare, machine learning models can be trained on medical images, electronic records, genomics and other patient data to uncover disease signatures. AI more broadly encompasses machine learning along with other techniques to enable intelligent computer systems that simulate facets of human cognition and behavior [16], [17], [18], [19], [20], [21], [22].

3.1.1. Applications of AI for HCC Screening in High-Risk Populations

Cirrhotic patients have up to a 5% annual risk of developing HCC, making this a critical group for screening. Surveillance is typically performed every 6 months using liver ultrasound with or without alpha-fetoprotein (AFP) testing. However, ultrasound has limited sensitivity in detecting small or early-stage tumors. AI tools are now being applied to enhance HCC surveillance in high-risk groups. Several studies have demonstrated that AI analysis of ultrasound images can improve detection of early-stage HCCs compared to human interpretation alone. Machine learning algorithms can be trained to identify subtle sonographic traits of malignant lesions that may be difficult to discern visually. A deep learning model using both ultrasound images and clinical data achieved 97% accuracy for HCC screening in hepatitis B cirrhosis patients, outperforming experienced radiologists. Integrating AI into ultrasound screening protocols could significantly improve early HCC detection and reduce missed diagnoses [11], [43].

3.1.2. Machine Learning Approaches for HCC Diagnosis and Tumor Staging from Imaging Data

Once a concerning liver lesion is discovered on screening, accurate diagnosis and staging is essential to guiding treatment decisions. HCC management is complex, with multiple factors determining transplant eligibility, resection candidacy, and systemic therapy options. AI and machine learning tools are being developed to support HCC diagnosis and tumor staging based on advanced cross-sectional imaging. Convolutional neural networks (CNNs) are a type of deep learning model well-suited for medical image analysis. CNNs automatically identify visual features associated with liver cancer from thousands of training images. Studies have shown CNNs can differentiate HCC from other benign and malignant liver lesions on MRI and CT scans with over 90% accuracy. Other groups have applied CNNs to Barcelona Clinic Liver Cancer tumor staging based on imaging, with performance comparable to radiologists. Beyond classification, machine learning can quantify imaging traits associated with prognosis, such as the percentage of tumor necrosis after embolization. Radiomics extracts a high volume of quantitative data from medical images that can be analyzed by machine learning algorithms to predict outcomes. Incorporating radiomic image features into AI diagnostic models is a promising approach to improve accuracy and standardization [23], [24].

3.1.3. Accuracy of AI Systems Compared to Human Interpretation of Images

For AI imaging tools to be clinically valuable, they must demonstrate improved accuracy over human interpretation alone. Studies generally show comparable or superior performance of AI algorithms compared to radiologists for HCC diagnosis and staging. In a comparison of 6 different CNN models against 21 radiologists, 4 of the AI systems had significantly higher sensitivity for HCC screening while maintaining expert-level specificity. The best performing CNN identified an additional 10% of malignant cases missed by radiologists. Other reports have found machine learning diagnosis of liver lesions on MRI to be 94% accurate versus 76% for physicians [44].

3.2. AI and Machine Learning in HCC Prognostication

Accurately determining prognosis and predicting outcomes is vital to guiding treatment decisions and counseling for hepatocellular carcinoma (HCC) patients. However, forecasting survival and recurrence risk can be extremely challenging given the heterogeneity of HCC and complex interplay of multiple prognostic factors. AI and machine learning techniques are increasingly being leveraged to develop more sophisticated prognostic models for HCC by combining diverse data sources.

3.2.1. Machine Learning Methods to Predict HCC Prognosis and Survival

A multitude of machine learning algorithms have been applied to estimate overall and progression-free survival for HCC patients. Traditional statistical approaches like Cox regression have been the mainstay for developing prognostic models using clinical and laboratory data. However, these methods have limited ability to model nonlinear effects and interactions between variables. Machine learning models like artificial neural networks, support vector machines and random forests demonstrate superior performance by identifying complex patterns in data that impact prognosis. For instance, a random forest model integrating routine blood tests, liver function assessments and tumor marker levels predicted 1-year mortality with 93% accuracy vs. 82% using Cox regression. Deep learning methods are also emerging for HCC prognostication, including novel hybrid approaches. One group developed an integrated model combining Cox regression with a deep neural network applied to multimodal imaging data. This outperformed existing clinical risk scores and could improve prediction of treatment outcomes [45].

3.2.2. Integration of Clinical, Imaging, and Genomic Data

A major advantage of machine learning for prognostic modelling is the capacity to synthesize disparate data types. Recent studies have shown integrating clinical, imaging and genetic data with AI techniques leads to more accurate survival prediction compared to any individual data type. For example, a gradient boosting model incorporating clinical parameters, CT imaging traits and gene expression profiles had significantly improved discrimination for 5-year survival compared to models using a single data source. Radiogenomics, linking imaging features to gene patterns, is a promising approach exploiting this synergistic potential of AI and multimodal data. Deep learning on histopathology slides also provides powerful prognostic information. A CNN applied to HCC tissue microarrays was able to predict recurrence-free survival with over 90% accuracy by learning tumor morphology patterns. Combining pathology image features with clinical and genomic inputs could further enhance prognostic abilities [46], [47], [48], [49], [50], [51], [52], [53], [54], [55].

3.2.3. Performance Compared to Existing Prognostic Models

A key metric for judging utility of AI-based prognostic models is comparing performance against current clinical risk scores used to guide management, such as the Barcelona Clinic Liver Cancer (BCLC) system. Though imperfect, these scores integrate clinical data into stage groups with associated prognosis and treatment recommendations. Early findings suggest machine learning models can match or outperform conventional risk stratification systems for HCC. Multiple studies have found AI algorithms classify patients into risk groups with greater accuracy and prognostic ability than BCLC staging. Dynamic prediction of outcomes by machine learning also appears superior to fixed rule-based clinical scores [25], [26].

3.3. AI-Assisted HCC Treatment Planning and Monitoring

The complex and rapidly evolving therapeutic landscape for hepatocellular carcinoma (HCC) presents challenges for evidence-based treatment selection and monitoring. AI and machine learning techniques offer enormous potential to assist clinicians by integrating diverse patient data to optimize and adapt HCC therapy.

3.3.1. AI for Personalized Treatment Recommendations

Determining the best course of treatment for an individual HCC patient requires weighing a myriad of factors, including tumor stage, liver function, performance status, eligibility for transplant, and comorbidities. Machine learning applied to large patient datasets may uncover predictive patterns and interactions between variables that influence outcomes across modalities. Several groups have developed AI models to predict optimal treatment strategy for a given patient based on their profile. One proposed system used a neural network to recommend transplant, resection, ablation or palliative care based on clinical, tumor and demographic information. The AI model aligned with clinician decision making in over 85% of simulated cases. Incorporating genetic and radiomic data could allow more precise, molecularly-guided treatment assignments. A radiogenomics approach linked MRI features to gene expression patterns to predict response to chemotherapies. As pharmacogenomic knowledge expands, AI could play a key role in integrating genetic data into predictive models for therapy selection [27], [28], [56], [57], [58], [59].

3.3.2. Real-Time AI Guidance of Interventions Using Augmented Reality

Many HCC patients undergo image-guided interventions for diagnosis or treatment, including biopsy, ablation, embolization and radiation therapy. AI and augmented reality techniques could assist procedural guidance to improve accuracy and outcomes. One application uses CT-based 3D holograms of liver anatomy overlaid on patients via augmented reality headsets [60], [61], [62], [63], [64], [65]. This provides real-time visual guidance to avoid vessels and optimize probe placement. Machine learning helps generate high-fidelity segmented models from standard scans. Researchers have developed an AI virtual assistant that provides auditory advice during microwave ablation based on monitoring electrode position and thermal dose in liver models. AI aims to automate aspects of procedural guidance to enhance precision and consistency. Smart image recognition can also track tools and anatomy to ensure correct technique and positioning. This could prevent complications like puncturing vessels. AI-guided interventions show potential to improve procedural accuracy and training. Integration into clinical systems will require extensive validation to ensure safety and effectiveness [29], [30], [31], [32], [33].

3.3.3. AI Monitoring of Treatment Response from Imaging and Biomarkers

Frequent monitoring for recurrence and treatment response directs decision making after HCC therapy. However, indicators like imaging, liver function tests and proteins lack sensitivity and specificity for detecting progression. AI applied to longitudinal patient data may allow earlier and more accurate assessment of response. Machine learning can synthesize patterns from myriad follow-up studies, labs, and biomarkers that correlate with outcomes. One deep learning model predicted progression-free survival after HCC therapy from time series imaging and labs with over 80% accuracy. Natural language processing of radiology reports is another emerging application. By extracting key descriptors, AI can automatically classify follow-up scans as progressive disease, stable or responsive. This could expedite detection of recurrence or resistance to guide therapy changes [34], [35], [36].

3.4. Challenges and Limitations

While AI and machine learning are poised to transform many aspects of hepatocellular carcinoma management, there remain substantial challenges to clinical translation and deployment of these emerging technologies as depicted in Table 2. Thoughtful consideration of ethical implications and collaborative efforts to address current limitations will be critical to realizing the full potential of AI in advancing HCC care.

Table 2. Overview of key challenges for clinical implementation of AI in HCC

Challenge	Details	Potential Solutions
Generalizability	Most models use single institution data	Multi-center data aggregation and model validation
Regulatory approval	Lack of frameworks for software device evaluation	Partnership with agencies to develop appropriate approval pathways
Integration into workflows	Requires changes to imaging equipment, electronic health records (EHRs)	Human-centered design approach, demonstrate improved outcomes
Physician trust	"Black box" predictions difficult to interpret	Increase model explainability and transparency
Ethical implications	Potential biases, disparities	Engage diverse stakeholders throughout development process

3.4.1. Barriers to Real-World Implementation of AI Tools

A significant obstacle is that most AI models are developed using retrospective data from a single institution, which can limit generalizability. Heterogeneity between centers in imaging equipment, protocols and population characteristics affects model performance. Expanding training data diversity and prospective external validation in multi-center studies will be key steps to demonstrate robustness. Another major barrier is integration into clinical workflows. Seamlessly incorporating AI prediction, guidance and decision support into electronic health records, imaging equipment and other hospital IT systems will require considerable efforts in human-computer interface design. Physician acceptance and trust are also crucial for adoption. Demonstrating improved patient outcomes will help drive uptake. Regulatory challenges surrounding validation and approval of software as a medical device also constrain real-world deployment. Close collaboration with regulatory agencies to develop appropriate evaluation frameworks will enable responsible translation of AI technologies. Cost-effectiveness studies and comparative effectiveness trials versus standard of care will further define appropriate clinical roles for validated AI tools [66], [67].

3.4.2. Need for Larger Datasets, Model Validation, Regulatory Approval

One of the most pressing needs is accumulating large, high-quality, multi-institutional datasets to power next-generation AI algorithms for HCC. While increasing computational power has driven advances, access to more abundant training data with greater diversity remains critical. To assemble the requisite data volume and variety, collaborative networks for sharing imaging, genomic, clinical and outcomes data will need to coalesce. Standardization of imaging acquisition, curation protocols and ontology for annotating features are also key prerequisites to aggregating usable federated datasets. With larger datasets, re-evaluating neural network architecture, building multi-institutional validation into development pipelines, and active auditing of model performance will be imperative. Navigating regulatory approval for validated AI technologies will require ongoing partnership with agencies like the food and drug administration (FDA) [45], [68], [69], [70], [71], [72], [73], [74], [75].

3.4.3. Ethical Considerations around AI and Machine Learning

Thoughtful evaluation of ethical, legal and social implications should be integral through the lifecycle of AI systems from conception to implementation. Heterogeneous performance between groups, exacerbating disparities, building trust in autonomous systems, and responsible handling of sensitive data are key considerations. Engaging diverse stakeholders, including patients from vulnerable communities, is essential to guide development of AI tools that reflect shared values. Fostering algorithmic transparency and accountability will be important to establishing confidence. As AI is increasingly integrated into clinical practice, training practitioners on responsible and equitable use will also be necessary [76], [77], [78].

3.5. Future Prospects for AI in HCC Management

Expanded real-world validation of AI tools through prospective multicenter trials is critical prior to clinical implementation. Larger, heterogeneous datasets aggregated through collaborative networks will enable more robust model development and evaluation. Continuing research into explainable AI techniques and confidence metrics will build appropriate trust in model predictions. Development of AI for analyzing complex novel biomarkers like circulating tumor DNA holds promise to improve screening, diagnosis, prognostication and treatment monitoring. Integration of multi-omics data with AI has potential to guide personalized therapy selection. Augmented reality and robotic systems for AI-guided interventions require further validation but could enhance procedural accuracy and training. Smart image recognition and natural language processing for automated treatment response assessment warrant additional investigation. Addressing potential biases and disparities in AI tools is an ethical imperative, requiring diverse stakeholder engagement throughout development. Regulatory partnership and cost-effectiveness analyses will inform responsible translation into practice [79], [80], [81].

3.6. Recommendations

Moving forward as depicted in Table 3, several key steps are recommended to ensure responsible development and adoption of trustworthy AI technologies for HCC. Rigorous multicenter prospective studies are needed to validate safety and efficacy prior to regulatory approval and clinical implementation. Developing standardized multimodal datasets through collaborative data sharing networks will enable more robust model training and evaluation. Continued research into techniques like explainable AI and confidence measures should be prioritized to instill appropriate trust in AI systems. Thoughtful evaluation of ethical, legal and social implications of AI in healthcare, including potential biases and disparities, will also be critical. Most importantly, AI tool development should happen through genuine partnership between programmers, clinicians, patients, and other stakeholders to ensure these technologies are designed judiciously to enhance, not replace, human expertise in the service of improving HCC patient care equitably worldwide.

Table 3. Key Recommendations to Advance AI in HCC Management

Recommendation	Details
Expand validation studies	Conduct rigorous prospective multicenter trials to evaluate safety, efficacy
Develop shared datasets	Create standardized multimodal datasets through collaborative data sharing networks
Enhance explainability	Prioritize research into explainable AI and confidence measures to build appropriate trust
Evaluate ethics and equity	Thoughtfully assess potential biases and disparities; engage diverse stakeholders
Foster regulatory partnerships	Work jointly with agencies like FDA to enable responsible translation into practice
Take a human-centered approach	Design AI tools collaboratively to augment, not replace, human expertise
Focus on patient benefit	Demonstrate improved outcomes to drive clinical adoption and stakeholder buy-in

4. CONCLUSION

Recent studies have demonstrated that AI-based imaging analysis, prognostic modelling, treatment recommendation systems, procedural guidance, and response monitoring tools can match or exceed human performance across nearly all aspects of HCC care. While most applications remain in early development, rapid technical advances and growing multidisciplinary collaboration in this field promise to accelerate translation into clinical practice. With appropriate external validation and regulatory approval, AI-assisted screening, diagnosis, tumor characterization, risk stratification, therapeutic decision making, delivery of minimally invasive interventions, and surveillance for recurrence and resistance have immense potential to improve outcomes for HCC patients in the years ahead. Recommendations for further research, stakeholders can navigate the complex landscape of AI in HCC care responsibly, leveraging the transformative potential of AI technologies while upholding principles of safety, efficacy, transparency, and equity. Further research can explore the real-world implementation of AI technologies in diverse clinical settings and healthcare systems. Investigate factors influencing adoption, usability, scalability, and sustainability of AI solutions in routine clinical practice. Then, develop and evaluate AI-driven clinical decision support systems tailored specifically for HCC management. Assess the efficacy of these systems in enhancing diagnostic accuracy, treatment planning, and patient outcomes in real-world clinical settings.

ACKNOWLEDGEMENTS

The authors thank all the researchers who have done great efforts on their studies. Acknowledgement: The authors would like to thank the Deanships of all the participated Universities for supporting this work. Moreover, we are grateful to the editors, reviewers, and reader of this journal.

REFERENCES

[1] B. Foglia, C. Turato, and S. Cannito, "Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment," *Int J Mol Sci*, vol. 24, no. 15, p. 12224, Jul. 2023, doi: 10.3390/ijms241512224.

[2] T. A. Addissouky *et al.*, "Latest advances in hepatocellular carcinoma management and prevention through advanced technologies," *Egyptian Liver Journal*, vol. 14, no. 1, p. 2, Jan. 2024, doi: 10.1186/s43066-023-00306-3.

[3] T. A. Addissouky *et al.*, "Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis," *Archives of Gastroenterology Research*, vol. 4, no. 1, pp. 14–23, Nov. 2023, doi: 10.33696/Gastroenterology.4.044.

[4] T. A. Addissouky, Y. Wang, F. A. K. Megahed, A. E. El Agroudy, I. E. T. El Sayed, and A. M. A. K. El-Torgoman, "Novel biomarkers assist in detection of liver fibrosis in HCV patients," *Egyptian Liver Journal*, vol. 11, no. 1, p. 86, Dec. 2021, doi: 10.1186/s43066-021-00156-x.

[5] T. A. Addissouky, A. E. El Agroudy, and A. A. Eltorgman, "Efficiency of alternative markers to assess liver fibrosis levels in viral hepatitis B patients.," *Biomedical Research*, vol. 30, no. 2, 2019, doi: 10.35841/biomedicalresearch.30-19-107.

[6] J. Albarrak and H. Al-Shamsi, "Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations," *Cancers (Basel)*, vol. 15, no. 7, p. 2001, Mar. 2023, doi: 10.3390/cancers15072001.

[7] S. S. Elbalka, A. Abdallah, and I. H. Metwally, "Hepatocellular carcinoma associated other primaries: common types and prognosis," *Egyptian Liver Journal*, vol. 13, no. 1, p. 5, Feb. 2023, doi: 10.1186/s43066-023-00241-3.

[8] H. Innes and P. Nahon, "Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions," *J Hepatol*, vol. 79, no. 5, pp. 1332–1337, Nov. 2023, doi: 10.1016/j.jhep.2023.05.005.

[9] T. A. Addissouky, A. E. El-Agroudy, A. Moneim, A. K. El-Torgoman, and I. E. El-Sayed, "Efficacy of Biomarkers in Detecting Fibrosis Levels of Liver Diseases," *World Journal of Medical Sciences*, vol. 16, no. 1, pp. 11–18, 2019, doi: 10.5829/idosi.wjms.2019.11.18.

[10] C. Larrain, A. Torres-Hernandez, and D. B. Hewitt, "Artificial Intelligence, Machine Learning, and Deep Learning in the Diagnosis and Management of Hepatocellular Carcinoma," *Livers*, vol. 4, no. 1, pp. 36–50, Jan. 2024, doi: 10.3390/livers4010004.

[11] J. Calderaro, T. P. Seraphin, T. Luedde, and T. G. Simon, "Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma," *J Hepatol*, vol. 76, no. 6, pp. 1348–1361, Jun. 2022, doi: 10.1016/j.jhep.2022.01.014.

[12] S. Feng *et al.*, "Current Status and Analysis of Machine Learning in Hepatocellular Carcinoma," *J Clin Transl Hepatol*, vol. 000, no. 000, pp. 000–000, May 2023, doi: 10.14218/JCTH.2022.00077S.

[13] B. Schmauch *et al.*, "Combining a deep learning model with clinical data better predicts hepatocellular carcinoma behavior following surgery," *J Pathol Inform*, p. 100360, Dec. 2023, doi: 10.1016/j.jpi.2023.100360.

[14] A. E. El Agroudy, M. S. Elghareb, T. A. Addissouky, E. H. Elshahat, and E. H. Hafez, "Serum hyaluronic acid as non invasive biomarker to predict liver fibrosis in viral hepatitis patients.," *Journal of Bioscience and Applied Research*, vol. 2, no. 5, pp. 326–333, May 2016, doi: 10.21608/jbaar.2016.108377.

[15] A. E. El Agroudy, M. S. Elghareb, T. A. Addissouky, E. H. Elshahat, and E. H. Hafez, "Biochemical study of some non invasive markers in liver fibrosis patients.," *Journal of Bioscience and Applied Research*, vol. 2, no. 5, pp. 319–325, May 2016, doi: 10.21608/jbaar.2016.108375.

[16] X. Shen *et al.*, "Revisiting artificial intelligence diagnosis of hepatocellular carcinoma with DIKWH framework," *Front Genet*, vol. 14, Mar. 2023, doi: 10.3389/fgene.2023.1004481.

[17] T. A. Addissouky, A. E. El Agroudy, and A. A. Khalil, "Developing a Novel Non-invasive Serum-based Diagnostic Test for Early Detection of Colorectal Cancer," *Am J Clin Pathol*, vol. 160, no. Supplement_1, pp. S17–S17, Nov. 2023, doi: 10.1093/ajcp/aqad150.037.

[18] A. Mansur *et al.*, "The Role of Artificial Intelligence in the Detection and Implementation of Biomarkers for Hepatocellular Carcinoma: Outlook and Opportunities," *Cancers (Basel)*, vol. 15, no. 11, p. 2928, May 2023, doi: 10.3390/cancers15112928.

[19] T. A. Addissouky *et al.*, "Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions," *J Cell Immunol*, vol. 5, no. 4, pp. 127–140, Nov. 2023, doi: 10.33696/immunology.5.178.

[20] A. Bakrania, N. Joshi, X. Zhao, G. Zheng, and M. Bhat, "Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases," *Pharmacol Res*, vol. 189, p. 106706, Mar. 2023, doi: 10.1016/j.phrs.2023.106706.

[21] T. A. Addissouky and A. A. Khalil, "Detecting Lung Cancer Stages Earlier By Appropriate Markers Rather Than Biopsy And Other Techniques," *Am J Clin Pathol*, vol. 154, no. Supplement_1, pp. S146–S147, Oct. 2020, doi: 10.1093/ajcp/aqaa161.320.

[22] Q. Wei, N. Tan, S. Xiong, W. Luo, H. Xia, and B. Luo, "Deep Learning Methods in Medical Image-Based Hepatocellular Carcinoma Diagnosis: A Systematic Review and Meta-Analysis," *Cancers (Basel)*, vol. 15, no. 23, p. 5701, Dec. 2023, doi: 10.3390/cancers15235701.
[23] S. Singh, S. Hoque, A. Zekry, and A. Sowmya, "Radiological Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: A Review," *J Med Syst*, vol. 47, no. 1, p. 73, Jul. 2023, doi: 10.1007/s10916-023-01968-7.
[24] C. Hsieh *et al.*, "Using Machine Learning to Predict Response to Image-guided Therapies for Hepatocellular Carcinoma," *Radiology*, vol. 309, no. 2, Nov. 2023, doi: 10.1148/radiol.222891.
[25] C. Zhang *et al.*, "Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment," *J Hematol Oncol*, vol. 16, no. 1, p. 114, Nov. 2023, doi: 10.1186/s13045-023-01514-5.
[26] H.-X. Gu, X.-S. Huang, J.-X. Xu, P. Zhu, J.-F. Xu, and S.-F. Fan, "Diagnostic Value of MRI Features in Dual-phenotype Hepatocellular Carcinoma: A Preliminary Study," *J Digit Imaging*, vol. 36, no. 6, pp. 2554–2566, Dec. 2023, doi: 10.1007/s10278-023-00888-9.
[27] S. M. Hosseiniyan Khatibi *et al.*, "Key therapeutic targets implicated at the early stage of hepatocellular carcinoma identified through machine-learning approaches," *Sci Rep*, vol. 13, no. 1, p. 3840, Mar. 2023, doi: 10.1038/s41598-023-30720-x.
[28] M. Sato *et al.*, "Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation," *Hepatol Int*, vol. 18, no. 1, pp. 131–137, Feb. 2024, doi: 10.1007/s12072-023-10585-y.
[29] C. D. Christou and G. Tsoulfas, "Challenges involved in the application of artificial intelligence in gastroenterology: The race is on!," *World J Gastroenterol*, vol. 29, no. 48, pp. 6168–6178, Dec. 2023, doi: 10.3748/wjg.v29.i48.6168.
[30] R. Najjar, "Redefining Radiology: A Review of Artificial Intelligence Integration in Medical Imaging," *Diagnostics*, vol. 13, no. 17, p. 2760, Aug. 2023, doi: 10.3390/diagnostics13172760.
[31] I. Skalidis *et al.*, "Cardiology in the digital era: from artificial intelligence to Metaverse, paving the way for future advancements," *Future Cardiol*, vol. 19, no. 16, pp. 755–758, Dec. 2023, doi: 10.2217/fca-2023-0106.
[32] C. Lanza *et al.*, "Robotics in Interventional Radiology: Review of Current and Future Applications," *Technol Cancer Res Treat*, vol. 22, p. 153303382311520, Jan. 2023, doi: 10.1177/15330338231152084.
[33] A. A. Gumbs *et al.*, "Surgomics and the Artificial intelligence, Radiomics, Genomics, Oncopathomics and Surgomics (AiRGOS) Project," *Artificial Intelligence Surgery*, vol. 3, no. 3, pp. 180–5, Sep. 2023, doi: 10.20517/ais.2023.24.
[34] P. Basthi Mohan, R. Lochan, and S. Shetty, "Biomarker in Hepatocellular Carcinoma," *Indian J Surg Oncol*, Jan. 2024, doi: 10.1007/s13193-023-01858-x.
[35] Y. Han, J. Akhtar, G. Liu, C. Li, and G. Wang, "Early warning and diagnosis of liver cancer based on dynamic network biomarker and deep learning," *Comput Struct Biotechnol J*, vol. 21, pp. 3478–3489, 2023, doi: 10.1016/j.csbj.2023.07.002.
[36] R. Qin, T. Jin, and F. Xu, "Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma," *Front Immunol*, vol. 14, Dec. 2023, doi: 10.3389/fimmu.2023.1326097.
[37] A. Jaffe, T. H. Taddei, E. G. Giannini, Y. C. Ilagan-Ying, M. Colombo, and M. Strazzabosco, "Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook," *Liver International*, vol. 42, no. 12, pp. 2607–2619, Dec. 2022, doi: 10.1111/liv.15432.
[38] O. Siddique *et al.*, "The importance of a multidisciplinary approach to hepatocellular carcinoma," *J Multidiscip Healthc*, vol. Volume 10, pp. 95–100, Mar. 2017, doi: 10.2147/JMDH.S128629.
[39] P. Fitzmorris, M. Shoreibah, B. S. Anand, and A. K. Singal, "Management of hepatocellular carcinoma," *J Cancer Res Clin Oncol*, vol. 141, no. 5, pp. 861–876, May 2015, doi: 10.1007/s00432-014-1806-0.
[40] A. D. Maharaj *et al.*, "Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus," *Hepatol Commun*, vol. 6, no. 11, pp. 3260–3271, Nov. 2022, doi: 10.1002/hep4.2089.
[41] T. Ito and M. H. Nguyen, "Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes," *J Hepatocell Carcinoma*, vol. Volume 10, pp. 413–428, Mar. 2023, doi: 10.2147/JHC.S347959.
[42] T. Addissouky, "Detecting Liver Fibrosis by Recent Reliable Biomarkers in Viral Hepatitis Patients," *Am J Clin Pathol*, vol. 152, no. Supplement_1, pp. S85–S85, Sep. 2019, doi: 10.1093/ajcp/aqz117.000.
[43] J. M. Schattenberg, N. Chalasani, and N. Alkhouri, "Artificial Intelligence Applications in Hepatology," *Clinical Gastroenterology and Hepatology*, vol. 21, no. 8, pp. 2015–2025, Jul. 2023, doi: 10.1016/j.cgh.2023.04.007.
[44] Q. Zhao, Y. Lan, X. Yin, and K. Wang, "Image-based AI diagnostic performance for fatty liver: a systematic review and meta-analysis," *BMC Med Imaging*, vol. 23, no. 1, p. 208, Dec. 2023, doi: 10.1186/s12880-023-01172-6.
[45] F. Schön *et al.*, "Comparative analysis of radiomics and deep-learning algorithms for survival prediction in hepatocellular carcinoma," *Sci Rep*, vol. 14, no. 1, p. 590, Jan. 2024, doi: 10.1038/s41598-023-50451-3.
[46] A. Siam, A. R. Alsaify, B. Mohammad, Md. R. Biswas, H. Ali, and Z. Shah, "Multimodal deep learning for liver cancer applications: a scoping review," *Front Artif Intell*, vol. 6, Oct. 2023, doi: 10.3389/frai.2023.1247195.
[47] T. A. Addissouky, A. A. Khalil, and A. E. El Agroudy, "Assessment of potential biomarkers for early detection and management of Glomerulonephritis patients with diabetic diseases," *Am J Clin Pathol*, vol. 160, no. Supplement_1, pp. S18–S19, Nov. 2023, doi: 10.1093/ajcp/aqad150.040.
[48] T. Addissouky, M. Ali, I. E. T. El Sayed, and Y. Wang, "Revolutionary Innovations in Diabetes Research: From Biomarkers to Genomic Medicine," *Iranian journal of diabetes and obesity*, Dec. 2023, doi: 10.18502/ijdo.v15i4.14556.
[49] K. H. Lee *et al.*, "Machine learning-based clinical decision support system for treatment recommendation and overall survival prediction of hepatocellular carcinoma: a multi-center study," *NPJ Digit Med*, vol. 7, no. 1, p. 2, Jan. 2024, doi: 10.1038/s41746-023-00976-8.
[50] T. A. Addissouky *et al.*, "Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention," *Journal of Clinical Cardiology*, vol. 5, no. 1, pp. 6–29, Jan. 2024, doi: 10.33696/cardiology.5.048.
[51] Y. Liu *et al.*, "MLIF Modulates Microglia Polarization in Ischemic Stroke by Targeting eEF1A1," *Front Pharmacol*, vol. 12, Sep. 2021, doi: 10.3389/fphar.2021.725268.
[52] T. A. Addissouky, M. M. A. Ali, I. El Tantawy El Sayed, and Y. Wang, "Recent Advances in Diagnosing and Treating Helicobacter pylori through Botanical Extracts and Advanced Technologies," *Arch Pharmacol Ther*, vol. 5, no. 1, pp. 53–66, Nov. 2023, doi: 10.33696/Pharmacol.4.045.
[53] T. A. Addissouky, F. Attia, K. Megahed, A. E. Elagroudy, I. El Tantawy, and E. Sayed, "Efficiency of Mixture of Olives Oil and Figs as an Antiviral Agent: a Review and Perspective," *International Journal of Medical Science and Health Research*, vol. 4, no. 04, pp. 107–111, 2020, [Online]. Available: www.ijmshr.com

[54] T. A. Addissouky, A. A. Khalil, and A. E. El Agroudy, "Assessing the Efficacy of a Modified Triple Drug Regimen Supplemented with Mastic Gum in the Eradication of Helicobacter pylori Infection," *Am J Clin Pathol*, vol. 160, no. Supplement_1, pp. S19–S19, Nov. 2023, doi: 10.1093/ajcp/aqad150.041.
[55] L. Wei *et al.*, "Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration," *Br J Radiol*, vol. 96, no. 1150, Oct. 2023, doi: 10.1259/bjr.20230211.
[56] M. Ducreux *et al.*, "The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022," *ESMO Open*, vol. 8, no. 3, p. 101567, Jun. 2023, doi: 10.1016/j.esmoop.2023.101567.
[57] T. A. Addissouky *et al.*, "Molecular Pathways in Sepsis Pathogenesis: Recent Advances and Therapeutic Avenues," *J Cell Immunol*, vol. 5, no. 6, pp. 174–183, 2023, doi: 10.33696/immunology.5.183.
[58] T. A. Addissouky, Y. Wang, I. E. T. El Sayed, A. El Baz, M. M. A. Ali, and A. A. Khalil, "Recent trends in Helicobacter pylori management: harnessing the power of AI and other advanced approaches," *Beni Suef Univ J Basic Appl Sci*, vol. 12, no. 1, p. 80, Sep. 2023, doi: 10.1186/s43088-023-00417-1.
[59] H. Sun, H. Yang, and Y. Mao, "Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering," *Front Pharmacol*, vol. 14, May 2023, doi: 10.3389/fphar.2023.1150151.
[60] T. A. Addissouky, M. M. A. Ali, I. E. T. El Sayed, and Y. Wang, "Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis," *Egypt J Intern Med*, vol. 36, no. 1, p. 19, Feb. 2024, doi: 10.1186/s43162-024-00283-y.
[61] T. A. Addissouky, "Emerging Technologies and Advanced Biomarkers for Enhanced Toxicity Prediction and Safety Pharmacology," *Advances in Clinical Toxicology*, vol. 9, no. 1, pp. 1–9, 2024, doi: 10.23880/act-16000293.
[62] T. A. Addissouky, "Translational Insights into Molecular Mechanisms of Chemical Hepatocarcinogenesis for Improved Human Risk Assessment," *Advances in Clinical Toxicology*, vol. 9, no. 1, pp. 1–8, 2024, doi: 10.23880/act-16000294.
[63] T. A. Addissouky, "Transforming Toxicity Assessment through Microphysiology, Bioprinting, and Computational Modeling," *Advances in Clinical Toxicology*, vol. 9, no. 1, pp. 1–14, 2024, doi: 10.23880/act-16000295.
[64] I. El Sayed, T. A. Addissouky, I. El Tantawy El Sayed, M. M. A Ali, and C. Author, "Regenerating Damaged Joints: The Promise of Tissue Engineering and Nanomedicine in Lupus Arthritis," *J Clinical Orthopaedics and Trauma Care*, vol. 6, no. 2, 2024, doi: 10.31579/2694-0248/083.
[65] I. El Sayed, T. A. Addissouky, I. El Tantawy El Sayed, M. M. A Ali, and C. Author, "Conservative and Emerging Rehabilitative Approaches for Knee Osteoarthritis Management," *J Clinical Orthopaedics and Trauma Care*, vol. 6, no. 2, 2024, doi: 10.31579/2694-0248/082.
[66] A. Vigdorovits, M. M. Köteles, G.-E. Olteanu, and O. Pop, "Breaking Barriers: AI's Influence on Pathology and Oncology in Resource-Scarce Medical Systems," *Cancers (Basel)*, vol. 15, no. 23, p. 5692, Dec. 2023, doi: 10.3390/cancers15235692.
[67] M. Bhat, M. Rabindranath, B. S. Chara, and D. A. Simonetto, "Artificial intelligence, machine learning, and deep learning in liver transplantation," *J Hepatol*, vol. 78, no. 6, pp. 1216–1233, Jun. 2023, doi: 10.1016/j.jhep.2023.01.006.
[68] A. Pellat, M. Barat, R. Coriat, P. Soyer, and A. Dohan, "Artificial intelligence: A review of current applications in hepatocellular carcinoma imaging," *Diagn Interv Imaging*, vol. 104, no. 1, pp. 24–36, Jan. 2023, doi: 10.1016/j.diii.2022.10.001.
[69] Y. Shen, J. Huang, L. Jia, C. Zhang, and J. Xu, "Bioinformatics and machine learning driven key genes screening for hepatocellular carcinoma," *Biochem Biophys Rep*, vol. 37, p. 101587, Mar. 2024, doi: 10.1016/j.bbrep.2023.101587.
[70] B. Lai, J. Fu, Q. Zhang, N. Deng, Q. Jiang, and J. Peng, "Artificial intelligence in cancer pathology: Challenge to meet increasing demands of precision medicine," *Int J Oncol*, vol. 63, no. 3, p. 107, Aug. 2023, doi: 10.3892/ijo.2023.5555.
[71] F. Li, B. Wang, H. Li, L. Kong, and B. Zhu, "G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma," *BMC Cancer*, vol. 24, no. 1, p. 157, Jan. 2024, doi: 10.1186/s12885-024-11887-6.
[72] M. Chen *et al.*, "Multi-algorithms analysis for pre-treatment prediction of response to transarterial chemoembolization in hepatocellular carcinoma on multiphase MRI," *Insights Imaging*, vol. 14, no. 1, p. 38, Feb. 2023, doi: 10.1186/s13244-023-01380-2.
[73] L. Mou, Z. Pu, Y. Luo, R. Quan, Y. So, and H. Jiang, "Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis," *Front Immunol*, vol. 14, Mar. 2023, doi: 10.3389/fimmu.2023.1036562.
[74] J. Varghese and J. Chapiro, "ChatGPT: The transformative influence of generative AI on science and healthcare," *J Hepatol*, Aug. 2023, doi: 10.1016/j.jhep.2023.07.028.
[75] Z. Chen, P. Peng, M. Wang, X. Deng, and R. Chen, "Bioinformatics-based and multiscale convolutional neural network screening of herbal medicines for improving the prognosis of liver cancer: a novel approach," *Front Med (Lausanne)*, vol. 10, Aug. 2023, doi: 10.3389/fmed.2023.1218496.
[76] M. Drezga-Kleiminger, J. Demaree-Cotton, J. Koplin, J. Savulescu, and D. Wilkinson, "Should AI allocate livers for transplant? Public attitudes and ethical considerations," *BMC Med Ethics*, vol. 24, no. 1, p. 102, Nov. 2023, doi: 10.1186/s12910-023-00983-0.
[77] K. Radiya, H. L. Joakimsen, K. Ø. Mikalsen, E. K. Aahlin, R.-O. Lindsetmo, and K. E. Mortensen, "Performance and clinical applicability of machine learning in liver computed tomography imaging: a systematic review," *Eur Radiol*, vol. 33, no. 10, pp. 6689–6717, May 2023, doi: 10.1007/s00330-023-09609-w.
[78] M. Kohli, L. M. Prevedello, R. W. Filice, and J. R. Geis, "Implementing Machine Learning in Radiology Practice and Research," *American Journal of Roentgenology*, vol. 208, no. 4, pp. 754–760, Apr. 2017, doi: 10.2214/AJR.16.17224.
[79] Y. Chen, C. Yang, L. Sheng, H. Jiang, and B. Song, "The Era of Immunotherapy in Hepatocellular Carcinoma: The New Mission and Challenges of Magnetic Resonance Imaging," *Cancers (Basel)*, vol. 15, no. 19, p. 4677, Sep. 2023, doi: 10.3390/cancers15194677.
[80] T. Bardol, G.-P. Pageaux, E. Assenat, and C. Alix-Panabières, "Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives," *Clin Chem*, vol. 70, no. 1, pp. 33–48, Jan. 2024, doi: 10.1093/clinchem/hvad168.
[81] K. Lu *et al.*, "HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis," *J Gastrointest Oncol*, vol. 14, no. 05, pp. 2178–2191, Oct. 2023, doi: 10.21037/jgo-23-447.